2025年政府工作：支持创新药发展，注重药品集采质量，鼓励中医药发展

Investment Rating - The report indicates a positive outlook for the pharmaceutical industry, particularly for innovative drug development, with a focus on quality and regulatory improvements [1][10]. Core Insights - The government emphasizes the importance of supporting innovative drug development, optimizing drug procurement policies, and enhancing quality assessments and regulations [1][3][10]. - The report highlights the expected improvement in the competitive landscape of the pharmaceutical industry due to policy support, which will shorten the return period on R&D investments for innovative drug companies [1][4][10]. - The increasing aging population and enhanced medical insurance payment capabilities are projected to sustain growth in downstream demand for the pharmaceutical industry [1][10]. Summary by Sections Encouragement of Innovative Drug Development - The 2025 government report reiterates support for innovative drugs, including the establishment of a pricing mechanism and a directory for innovative drugs [3][4]. - Policies introduced in 2024 aim to protect innovative drug companies from early price reductions due to procurement [3][4]. Focus on Quality in Drug Procurement - The report states that drug procurement policies will be optimized to emphasize quality assessments and regulations, transitioning from merely promoting procurement to optimizing it [5][6]. - Historical data shows that the average price reduction in drug procurement has been between 52% and 59%, with the most competitive procurement round in 2024 seeing reductions exceeding 70% [5][7]. Enhancement of Medical Insurance Payment Capabilities - The government plans to increase per capita financial subsidies for medical insurance and improve the overall payment capabilities of the medical insurance fund [7][8]. - The expansion of the medical insurance coverage to include innovative drugs is anticipated as the new drug directory is implemented [7][8]. Encouragement of Traditional Chinese Medicine Development - The report outlines ongoing support for the development of Traditional Chinese Medicine (TCM), including the establishment of innovation centers and the integration of digital technologies [9][10]. - Policies aimed at modernizing and industrializing TCM are expected to enhance the operational efficiency of TCM enterprises [9][10]. Conclusion - The report concludes that the pharmaceutical industry is poised for recovery in growth rates, with improved external environments for innovative drugs and TCM enterprises [10][11].